Non-a, Non-b Hepatitis Virus Or Hepatitis C Virus Patents (Class 424/228.1)
-
Publication number: 20110293723Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: Selecta Biosciences, Inc.Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
-
Publication number: 20110293658Abstract: A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a combination thereof.Type: ApplicationFiled: November 12, 2009Publication date: December 1, 2011Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Vincenzo Cerundolo, Carmela De Santo
-
Patent number: 8067228Abstract: Peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N° 1, a peptide B having at least the amino acid sequence of SEQ ID N° 45, a peptide C having at least the amino acid sequence of SEQ ID N° 127, and a peptide D having at least the amino acid sequence of SEQ ID N° 174. The compositions can be used, in particular, in the preparation of active pharmaceutical compositions against the hepatitis C virus.Type: GrantFiled: September 16, 2008Date of Patent: November 29, 2011Assignees: Transgene SA, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Anne Fournillier, Nourredine Himoudi, Genevieve Inchauspe
-
Publication number: 20110286964Abstract: The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing dieases or disorders such as viral infections and virus-related disorders.Type: ApplicationFiled: August 19, 2009Publication date: November 24, 2011Inventors: Cecil D. Kwong, F. George Njoroge, Subramaniam Ananthan, Feng Geng, Hollis S. Kezar, III, Joseph A. Maddry, John J. Piwinski, Robert C. Reynolds, John A. Secrist, III, Neng-Yang Shih
-
Patent number: 8057162Abstract: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.Type: GrantFiled: May 26, 2009Date of Patent: November 15, 2011Assignees: Transgene S.A., Institut National de la Sante et De La Recherche MedicaleInventors: Anne Fournillier, Genevieve Inchauspe, Jean-Daniel Abraham, Maria Dimitrova-Tchomakov, Marie Parnot
-
Publication number: 20110262482Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: Kineta, Inc.Inventors: Shawn P. Iadonato, Kristin Bedard
-
Publication number: 20110256098Abstract: Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.Type: ApplicationFiled: September 18, 2009Publication date: October 20, 2011Inventors: David Apelian, Richard C. Duke, Alex Franzusoff
-
Patent number: 8025887Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: October 28, 2009Date of Patent: September 27, 2011Assignees: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention, Mahidol UniversityInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Patent number: 8026092Abstract: The present invention provides replication competent polynucleotides that include a coding sequence encoding a hepatitis C virus polyprotein having adaptive mutations. The invention also includes methods for malting replication competent polynucleotides, identifying a compound that inhibits replication of a replication competent polynucleotide, selecting a replication competent polynucleotide, and detecting a replication competent polynucleotide.Type: GrantFiled: December 1, 2004Date of Patent: September 27, 2011Assignee: Board of Regents, the University of Texas SystemInventors: Stanley M. Lemon, MinKyung Yi
-
Patent number: 8021835Abstract: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.Type: GrantFiled: May 4, 2007Date of Patent: September 20, 2011Assignee: The Rockefeller UniversityInventors: Charles Rice, Matthew J. Evans, Thomas Von Hahn
-
Patent number: 8022197Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.Type: GrantFiled: September 16, 2004Date of Patent: September 20, 2011Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
-
Publication number: 20110223197Abstract: Mucosal and systemic administration of compositions comprising alphavirus replicon particles to induce immune responses in a subject is described.Type: ApplicationFiled: October 17, 2006Publication date: September 15, 2011Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventor: Michael Vajdy
-
Patent number: 8007816Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: August 22, 2008Date of Patent: August 30, 2011Assignee: GlobeImmune, Inc.Inventors: Richard C Duke, Alex Franzusoff, Aurelia Haller, Thomas H King
-
Publication number: 20110177110Abstract: Immunogenic HCV E1E2809 DNA compositions and methods of using the same are described. The compositions comprise HCV E1E2809 DNA adsorbed to cationic microparticles, such as poly(lactide-co-glycolide) (PLG) microparticles.Type: ApplicationFiled: March 18, 2011Publication date: July 21, 2011Inventors: DEREK O' HAGAN, MICHAEL HOUGHTON, MANMOHAN SINGH
-
Publication number: 20110159039Abstract: Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.Type: ApplicationFiled: August 30, 2010Publication date: June 30, 2011Inventors: Michael Houghton, Mark Selby, Sergio Abrignani, Jens Martin Heile, Derek O'Hagan
-
Publication number: 20110142912Abstract: The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.Type: ApplicationFiled: December 31, 2007Publication date: June 16, 2011Inventors: Christian Moser, Andreas Kammer, Rinaldo Zurbriggen
-
Publication number: 20110129489Abstract: The present invention relates to the generation of an immune response against a target antigen using a DNA and viral vector in a specific administration pattern.Type: ApplicationFiled: July 7, 2008Publication date: June 2, 2011Inventors: Erik Depla, Annegret Van Der Aa, Sofie De Schepper, Stany Depraetere, Karen De Vreese
-
Publication number: 20110129498Abstract: The present invention relates to CD81-binding peptides of the hepatitis virus C(HCV) E2 glycoprotein, which are devoid of or mutated within the amino-terminal 27 amino acids of the mature E2 envelope glycoprotein, or variant thereof which retains the ability to bind to CD81. Furthermore, the present invention provides polypeptides comprising said CD81-binding peptide, polynucleotides encoding the CD81-binding peptide, and expression cassettes and vectors comprising the polynucleotide of the invention. Moreover, the present invention relates to compositions comprising the CD81-binding peptide, the polynucleotide encoding the CD81-binding peptide, the expression cassette, or the vector, and an adjuvant. Furthermore, the present invention provides a pharmaceutical composition comprising the CD81-binding peptide, the polynucleotide, the expression cassette, the vector, or the composition of the invention, and a pharmaceutically acceptable excipient, carrier, or diluent.Type: ApplicationFiled: June 3, 2009Publication date: June 2, 2011Applicant: OKAIROS AGInventors: Riccardo Cortese, Alfredo Nicosia
-
Patent number: 7951531Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a-GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.Type: GrantFiled: February 1, 2006Date of Patent: May 31, 2011Assignee: University of Iowa Research FoundationInventors: Jack T. Stapleton, Jinhua Xiang, Qing Chang, James McLinden
-
Patent number: 7943149Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: GrantFiled: December 29, 2009Date of Patent: May 17, 2011Assignee: ChronTech Pharma ABInventor: Matti Sallberg
-
Publication number: 20110091495Abstract: A construct comprising the ectodomain of the Hepatitis C Virus (HCV) E2 sequence and a mammalian expression system therefor is disclosed. The construct comprises a CMV promoter, prolactin signal sequence, the ectodomain of HCV E2 sequence truncated at aa 664, a thrombin cleavage site and a human Fc domain. The method also relates to an expression system for the construct, which is stably expressed in human embryonic kidney cells 293T. Continuous protein expression in a bioreactor allows for 4 mg of purified protein per liter of cell supernatant.Type: ApplicationFiled: April 22, 2009Publication date: April 21, 2011Inventors: Joseph Marcotrigiano, Jillian L. Whidby, Arash Grakoul
-
Publication number: 20110086006Abstract: The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.Type: ApplicationFiled: December 17, 2010Publication date: April 14, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Chao Lin, Kai Lin
-
Publication number: 20110081381Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.Type: ApplicationFiled: September 29, 2010Publication date: April 7, 2011Applicant: CHRONTECH PHARMA ABInventor: Matti Sallberg
-
Patent number: 7919312Abstract: A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that improves the efficiency of establishing persistently replicating HCV RNA in cell culture. This self-replicating polynucleotide molecule contains, contrary to all previous reports, a 5?-NTR that can be either an A as an alternative to the G already disclosed and therefore provides an alternative to existing systems comprising a self-replicating HCV RNA molecule. The G?A mutation gives rise to HCV RNA molecules that, in conjunction with mutations in the HCV non-structural region, such as the G(2042)C/R mutations, possess greater efficiency of transduction and/or replication. These RNA molecules when transfected in a cell line are useful for evaluating potential inhibitors of HCV replication.Type: GrantFiled: March 28, 2006Date of Patent: April 5, 2011Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: George Kukolj, Arnim Pause
-
Patent number: 7888004Abstract: Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupts the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.Type: GrantFiled: October 3, 2008Date of Patent: February 15, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Doris Coit, Angelica Medina-Selby, Mark Selby, Michael Houghton
-
Patent number: 7883843Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.Type: GrantFiled: July 19, 2004Date of Patent: February 8, 2011Assignee: Vaccine Research Institute of San DiegoInventors: David R. Milich, Jean-Noel Billaud
-
Publication number: 20110020398Abstract: The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.Type: ApplicationFiled: December 17, 2009Publication date: January 27, 2011Inventors: Geneviève Inchauspe, Anne Fournillier, Nourredine Himoudi, Perrine Martin
-
Publication number: 20110014229Abstract: The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.Type: ApplicationFiled: July 14, 2009Publication date: January 20, 2011Applicant: Sanofi Pasteur Biologics Co.Inventors: Harold Kleanthous, Charles Miller, Larisa Oros
-
Publication number: 20110014226Abstract: A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is a pathogen-derived antigen and the antibody decreases or inhibits virulence of the pathogen when bound to the antigen (e.g., a neutralizing antibody, antibody with serum bactericidal activity, etc.). In another embodiment, the antigen is a self-antigen (autoantigen) and the antibody is an autoantibody that is known to be associated with a pathological condition (e.g., autoimmune disorder). Compounds that bind to the antigen or antibody disrupt binding can be used as therapeutics to decrease or inhibit the autoimmune disorder.Type: ApplicationFiled: March 17, 2009Publication date: January 20, 2011Inventors: Michael J. Caulfield, Michael D. Miller, Joseph G. Joyce, Paul D. Zuck, Krista L. Getty, Vadim Dudkin, Elizabeth A. Ottinger
-
Publication number: 20110014209Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.Type: ApplicationFiled: August 24, 2007Publication date: January 20, 2011Inventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
-
Patent number: 7871625Abstract: Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.Type: GrantFiled: August 26, 2005Date of Patent: January 18, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Chien, Doris Coit, Carlos George-Nascimento, Sansan Lin, Angelica Medina-Selby, Laura Tandeske
-
Publication number: 20110002961Abstract: A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of said antigen on their surface by an HLA class I (or equivalent) molecule, the method comprising administering to the patient a therapeutically effective amount of either antigen presenting cells which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen. In a related set of claims said method refers to the administration to a patient of therapeutic levels of cytotoxic T lymphocytes (CTL) which recognize at least part of said antigen when presented by an HLA class I (or equivalent) molecule on the surface of a cell and which these CTL were stimulated by the antigen presenting cells, mentioned in the first section, which have been gene delivered with the interleukin 12 (IL-12) gene plus a relevant antigen.Type: ApplicationFiled: March 3, 2009Publication date: January 6, 2011Inventor: Paul Hermonat Hermonat
-
Publication number: 20100322972Abstract: The use of polycationic compounds for the preparation and manufacturing of medicaments, pharmaceutical compositions, especially vaccines for the treatment of patients with HCV chronic infections are disclosed.Type: ApplicationFiled: May 5, 2010Publication date: December 23, 2010Inventors: JÜRGEN FRISCH, ERICH TAUBER, VERA BÜRGER, CHRISTOPH KLADE, MICHAEL BUSCHLE, KATHERINE COHEN
-
Publication number: 20100316669Abstract: Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.Type: ApplicationFiled: April 27, 2009Publication date: December 16, 2010Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Santiago Duenas Carrera, Juan Morales Grillo, Liz Alvarez-Lajonchere Ponce de Leon, Alexis Musacchio Lasa, Rolando Pajon Feyt, Ariel Vina Rodriguez, Julio C. Alvarez Obregon, Nelson Acosta Rivero, Gillian Martinez Donato
-
Publication number: 20100310605Abstract: An anti-HCV vaccine, which is prepared through recombination of an NS gene in series, including NS3/NS4 and NS4/NS5, with an adenovirus vector. The preparation methods and uses of the anti-HCV vaccine.Type: ApplicationFiled: December 18, 2007Publication date: December 9, 2010Applicant: Peking University People's HospitalInventors: Lai Wei, Yuan Tian
-
Publication number: 20100297170Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: ApplicationFiled: April 13, 2010Publication date: November 25, 2010Inventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Patent number: 7837996Abstract: The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antibodies. Furthermore, the invention relates to a method of treating or preventing HCV infection by administration of a vaccine composition comprising the monoclonal antibodies of the invention.Type: GrantFiled: July 6, 2007Date of Patent: November 23, 2010Assignee: Molecules of Man ABInventors: Katarina Drakenberg, Mats A. A. Persson
-
Patent number: 7838006Abstract: A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.Type: GrantFiled: April 14, 2008Date of Patent: November 23, 2010Assignee: Immunitor USA Inc.Inventors: Vichai Jirathitikal, Aldar Bourinbaiar
-
Publication number: 20100285060Abstract: The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen.Type: ApplicationFiled: May 10, 2010Publication date: November 11, 2010Applicant: SciClone Pharmaceuticals, Inc.Inventor: Cynthia W. TUTHILL
-
Publication number: 20100278865Abstract: This invention relates to a nucleic acid comprising a nucleic acid sequence encoding an epitope tag peptide in the hypervariable region 1 of the E2 protein of naturally occurring or chimeric hepatitis C virus (HCV) genome, an epitope-tagged HCV particle encoded by such nucleic acid, and a method for purifying the HCV particles at a high purity in a simple manner with the use of an anti-epitope tag antibody-immobilized support.Type: ApplicationFiled: July 11, 2008Publication date: November 4, 2010Inventors: Takaji Wakita, Tetsuro Suzuki, Hitoshi Takahashi
-
Publication number: 20100278857Abstract: The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided.Type: ApplicationFiled: April 8, 2004Publication date: November 4, 2010Applicant: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Mansour Mohamadzadeh, Tyler J. Curiel, Cindy A. Morris
-
Publication number: 20100260715Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: March 1, 2010Publication date: October 14, 2010Inventors: Yat Sun Or, Ce Wang, Lu Ying, Xiaowen Peng, Yao-Ling Qiu
-
Publication number: 20100247571Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.Type: ApplicationFiled: March 26, 2010Publication date: September 30, 2010Applicant: ACADEMIA SINICAInventors: Chi-Huey Wong, Che Ma, Cheng-Chi Wang, Juine-Ruey CHEN
-
Publication number: 20100239607Abstract: The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.Type: ApplicationFiled: June 1, 2010Publication date: September 23, 2010Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventors: Derek O'Hagan, Manmohan Singh
-
Publication number: 20100239608Abstract: The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitable as an inoculating agent as well as a therapeutic agent for tissue regeneration. In addition a process is described for determining sequence modifications that serve for the stabilisation and translation optimisation of mRNA.Type: ApplicationFiled: May 26, 2010Publication date: September 23, 2010Applicant: CUREVAC GMBHInventors: FLORIAN VON DER MÜLBE, INGMAR HOERR, STEVE PASCOLO
-
Publication number: 20100226882Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: February 17, 2010Publication date: September 9, 2010Inventors: Yat Sun Or, Xiaowen Peng, Ce Wang, Lu Ying, Datong Tang, Yao-Ling Qiu
-
Publication number: 20100226886Abstract: The invention is directed in part to methods for treating and/or controlling hepatitis C in a patient. The methods are directed in part to combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and at least one other active agent.Type: ApplicationFiled: October 2, 2009Publication date: September 9, 2010Inventor: Willliam J. Sasiela
-
Patent number: 7785595Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention.Type: GrantFiled: April 18, 2005Date of Patent: August 31, 2010Assignee: Yeda Research and Development Company LimitedInventors: Shlomo Dagan, Rachel Eren, Hemant Kumar Misra, Walter G. Gowan, Jr., Sandra O'Connor
-
Patent number: 7785875Abstract: There are provided a polynucleotide encoding HCV epitopes, an immunogenic composition including same, and a method of inducing an HCV-specific immune response using same.Type: GrantFiled: November 3, 2008Date of Patent: August 31, 2010Assignee: Mogam Biotechnology Research InstituteInventors: Yu Kyeong Hwang, Okjae Lim, Hyejin Chung
-
Publication number: 20100215696Abstract: The present invention relates an efficiently replicating a modified hepatitis virus (HCV) mutant, and a modified HCV further comprising reporter gene, a method of preparing HCV vaccine using the same, and a method of screening anti-HCV material using the same. The present invention is to overcome the defect that the conventional HCV cell culture systems are unable to produce a sufficient amount of virus, thereby causing it difficult to efficiently induce or measure HCV infection. Because the present invention can allow production of HCV in a large amount an efficiently observing HCV infection in a living cell, it can make it possible to achieve many studies that were previously highly challenging, including studies on infection routes, and assembly and release of HCV. In addition, the present invention contributes to studies for searching anti-HCV agents being inhibiting all stages of the HCV life cycle, not being limited to HCV replication.Type: ApplicationFiled: April 28, 2008Publication date: August 26, 2010Inventors: Sung-Key Jang, Chon Saeng Kim